Obinutuzumab (GA101) - A different anti-CD20 antibody with great expectations

    Research output: Contribution to journalArticlepeer-review

    Original languageEnglish
    Pages (from-to)543-545
    Number of pages2
    JournalExpert opinion on biological therapy
    Volume12
    Issue number5
    DOIs
    Publication statusPublished - May 2012

    Keywords

    • CD20
    • immunotherapy
    • lymphoid malignancies
    • mAb
    • newer agents

    Cite this